Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
7,580.06
(
0.22%
)
US TECH 100
29,634.40
(
0.35%
)
Dow Jones
51,032.46
(
0.72%
)
Brent Oil
93.92
(
2.80%
)
Bitcoin
72,963.70
(
-0.80%
)
News Focus
News Focus

Replies to post #983 on Fate Therapeutics Inc (FATE)

Replies to #983 on Fate Therapeutics Inc (FATE)
icon url

NY1972

05/24/26 12:09 PM

#984 RE: jondoeuk #983

They can't finish P1 dosing study by June if they didn't focus on tumor type and regiment. MSS CRC and Cetuximab + FT839 was chosen before P1 started.